Company intelligence / Profile preview

LOTTE BIOLOGICS

Seoul, Seoul, South Korealottebiologics.com ↗

Ownership: Private
Employees: ~500
Development stage: Commercial

Overview

LOTTE BIOLOGICS does not have its own clinical results or pipeline but provides end-to-end development and GMP/commercial manufacturing services for global biopharma clients. The Syracuse Bio Campus has received over 62 regulatory approvals from agencies such as FDA, EMA, PMDA, MFDS for products manufactured at the site

Therapeutic areas: Other
Modalities: Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)Other biologics/drug substances
Industry: Contract Manufacturing Organization

Partnerships

No specific partnerships named in sources; collaborates with global pharmaceutical/biotech companies as contract clients.

Beyond the preview

Go deeper on LOTTE BIOLOGICS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LOTTE BIOLOGICS.

Explore the full profile